Evidence map›Paper›PMID 41283690›Full record

ArticleJournal of virology2025

A novel bispecific nanobody protects mice against RSV infection via intranasal administration.

Min Zhang, Liuxing Qin, Raoqing Guo, Jinwei Li, Si Huang, Chen Sheng, Yijia Xiang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Nanobodies targeting SARS-CoV-2 variants.Acta pharmaceutica Sinica. B · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Min Zhang *State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.ORCID 0009-0002-3204-4553
Liuxing Qin *State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China.
Raoqing Guo *Guangzhou National Laboratory, Bio-island, Guangzhou, Guangdong, China.
Jinwei LiGuangzhou Medical University, Guangzhou, Guangdong, China.
Si HuangGuangzhou Medical University, Guangzhou, Guangdong, China.
Chen ShengGuangzhou Medical University, Guangzhou, Guangdong, China.
Yijia XiangGuangzhou Medical University, Guangzhou, Guangdong, China.

Funding

State Key Laboratory of Respiratory Disease SKLRD-Z-202409
6 · The paper itself

Abstract

Respiratory syncytial virus (RSV) is the leading cause of respiratory infection-related hospitalizations in children younger than 5 years. Neutralizing nanobody-based interventions represent a promising strategy against RSV. Here, we identify a novel nanobody (4-H1) targeting the RSV prefusion F (pre-F) protein, which demonstrates potent neutralization against both RSV A and B subtypes. Epitope characterization via binning assays, molecular docking, and mutational analyses revealed that 4-H1 interacts with a unique region within antigenic site Ø by engaging critical residues L207, K209, and the K65-N67-C69 cluster. To improve the

Indexed as

Antibodies, BispecificAntibodies, ViralRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsSingle-Domain AntibodiesAdministration, IntranasalAnimalsAntibodies, NeutralizingEpitopesFemaleHumansMiceMice, Inbred BALB CMolecular Docking SimulationViral Fusion ProteinsAntibodies, BispecificAntibodies, NeutralizingAntibodies, ViralEpitopesSingle-Domain AntibodiesViral Fusion Proteinsalbumin-bindingantigenic site Øbispecific nanobodiesintranasal administrationrespiratory syncytial virus

Identifiers

PMID41283690
PMCPMC12724135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.